DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

Conclusions: These data suggest DEK overexpression as a crucial event for the emergence of an aggressive phenotype in colorectal cancer and its potential role as biomarker for irinotecan response in those patients with KRAS wild-type status.

http://www.biomedcentral.com/1471-2407/14/965

Source: Epidemiologic Perspectives and Innovations - December 16, 2014 Category: Epidemiology Authors: Javier Martinez-UserosMaria Rodriguez-RemirezAurea Borrero-PalaciosIrene MorenoArancha CebrianTeresa Gomez del PulgarLaura del Puerto-NevadoRicardo Vega-BravoAlberto Puime-OtinNuria PerezSandra ZazoClara SeninMaria J Fernandez-AceñeroMaria S SoengasFeder Source Type: research